Crossbow Therapeutics closed a $77 million Series B round to advance its lead T-cell engager CBX-250 into later clinical completion. The company said the funding will support completion of its phase I trial in relapsed or refractory myeloid malignancies including acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndromes, and chronic myelomonocytic leukemia. Crossbow’s T-Bolt platform uses antibodies designed to mimic T-cell receptor recognition of peptide fragments presented by HLA complexes on target cells, aiming to reach a broader “cancer proteome” rather than only surface proteins. The company also nominated a second candidate, CBX-663, targeting an HLA-complexed telomerase reverse transcriptase-derived peptide, and said an IND filing is planned for spring 2026. The financing highlights continued appetite for early-stage T-cell engager programs in oncology where immunogenicity, target reach, and HLA presentation are central differentiators. Crossbow’s ability to secure an oversubscribed growth round indicates that investors remain willing to fund modality platforms while early clinical readouts are still being collected.